{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T14:32:41Z","timestamp":1772807561224,"version":"3.50.1"},"reference-count":32,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2019,3,19]],"date-time":"2019-03-19T00:00:00Z","timestamp":1552953600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"LEO Pharma"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2019,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Plaque psoriasis has significant impact on patients\u2019 quality of life. Topical therapy is considered the treatment mainstay for mild\u2010to\u2010moderate disease according to guidelines. Calcipotriol\/betamethasone dipropionate (Cal\/<jats:styled-content style=\"fixed-case\">BD<\/jats:styled-content>) [0.005%\/0.05%] aerosol foam is indicated for psoriasis vulgaris treatment in adults. Cal\/<jats:styled-content style=\"fixed-case\">BD<\/jats:styled-content> foam trials demonstrated improved efficacy and similar safety in this population. Psoriasis treatment is complicated by the broad range of disease presentation, variability and therapeutic options; particularly decisions on transition from topical to non\u2010biologic systemic treatment are difficult. Assessing comparative effectiveness of treatment options provides meaningful value to treatment decisions.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To compare efficacy of Cal\/<jats:styled-content style=\"fixed-case\">BD<\/jats:styled-content> foam individual patient data from pooled trials with efficacy of non\u2010biologic systemic treatments based on aggregated patient characteristics and treatment outcomes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Individual data from four Cal\/<jats:styled-content style=\"fixed-case\">BD<\/jats:styled-content> foam trials in 749 psoriasis patients were pooled to conduct matching\u2010adjusted indirect comparisons. Literature review identified non\u2010biologic systemic treatment trials where methods, populations and outcomes align with Cal\/<jats:styled-content style=\"fixed-case\">BD<\/jats:styled-content> foam trials. Of 3090 screened publications, four studies of apremilast, methotrexate, acitretin or fumaric acid esters (<jats:styled-content style=\"fixed-case\">FAE<\/jats:styled-content>) were included.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>After baseline matching, patients treated with 4\u00a0weeks of Cal\/<jats:styled-content style=\"fixed-case\">BD<\/jats:styled-content> foam had greater Physician's Global Assessment 0\/1 response compared to those treated with 16\u00a0weeks of apremilast (52.7% vs. 30.4%; <jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00.001). Patients treated with Cal\/<jats:styled-content style=\"fixed-case\">BD<\/jats:styled-content> foam had significantly greater Psoriasis Area and Severity Index (<jats:styled-content style=\"fixed-case\">PASI<\/jats:styled-content>) 75 response at Week 4 compared to 16\u00a0weeks of apremilast treatment (51.1% vs. 21.6%; <jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00.001). Cal\/<jats:styled-content style=\"fixed-case\">BD<\/jats:styled-content> foam patients demonstrated significantly greater <jats:styled-content style=\"fixed-case\">PASI<\/jats:styled-content> 75 response improvements at Week 4 vs. 12\u00a0weeks of methotrexate (50.8% vs. 33.5%; <jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00.001) or acitretin (50.9% vs. 31.7%; <jats:italic>P<\/jats:italic>\u00a0=\u00a00.009), and comparable response to <jats:styled-content style=\"fixed-case\">FAE<\/jats:styled-content> (42.4% vs. 47.0%; <jats:italic>P<\/jats:italic>\u00a0=\u00a00.451).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Despite recent treatment advances, unmet needs for psoriasis patients remain. Cal\/<jats:styled-content style=\"fixed-case\">BD<\/jats:styled-content> foam offers improved efficacy in baseline matched psoriasis patients compared to apremilast, methotrexate or acitretin, and comparable efficacy to <jats:styled-content style=\"fixed-case\">FAE<\/jats:styled-content>.<\/jats:p><\/jats:sec>","DOI":"10.1111\/jdv.15369","type":"journal-article","created":{"date-parts":[[2018,11,25]],"date-time":"2018-11-25T14:16:53Z","timestamp":1543155413000},"page":"1107-1115","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Calcipotriol plus betamethasone dipropionate aerosol foam vs. apremilast, methotrexate, acitretin or fumaric acid esters for the treatment of plaque psoriasis: a matching\u2010adjusted indirect comparison"],"prefix":"10.1111","volume":"33","author":[{"given":"A.P.","family":"Bewley","sequence":"first","affiliation":[{"name":"Whipps Cross University Hospital &amp; The Royal London Hospital (Barts Health) NHS Trust London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.H.","family":"Shear","sequence":"additional","affiliation":[{"name":"Sunnybrook Health Sciences Centre Toronto ON Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.G.","family":"Calzavara\u2010Pinton","sequence":"additional","affiliation":[{"name":"Dermatology Department University of Brescia Brescia Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.B.","family":"Hansen","sequence":"additional","affiliation":[{"name":"LEO Pharma Ballerup Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.E.","family":"Nyeland","sequence":"additional","affiliation":[{"name":"LEO Pharma Ballerup Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Signorovitch","sequence":"additional","affiliation":[{"name":"Analysis Group Boston MA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2019,3,19]]},"reference":[{"key":"e_1_2_7_2_1","unstructured":"World Health Organization.Global report on psoriasis. [WWW document]2016. URLhttp:\/\/apps.who.int\/iris\/handle\/10665\/204417(last accessed: 25 April 2018)."},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2008.12.032"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0052935"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-015-0169-x"},{"key":"e_1_2_7_6_1","unstructured":"National Institute for Health and Care Excellence.Psoriasis: assessment and management. Clinical Guideline CG153. [WWW document]2012. URLhttps:\/\/www.nice.org.uk\/guidance\/cg153(last accessed: 23 April 2018)."},{"key":"e_1_2_7_7_1","first-page":"18","article-title":"Psoriasis treatment cost comparison: biologics versus home phototherapy","volume":"10","author":"Hyde K","year":"2018","journal-title":"Am J Pharm Benefits"},{"key":"e_1_2_7_8_1","unstructured":"Summary of product characteristics: Enstilar Leo Pharma May 2017. [WWW document] URLhttps:\/\/www.medicines.org.uk\/emc\/files\/pil.2139.pdf(last accessed: 11 July 2018)."},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-016-0125-6"},{"key":"e_1_2_7_10_1","first-page":"S33","article-title":"Enhanced in\u00a0vitro skin penetration and antipsoriatic effect of fixed combination calcipotriol plus betamethasone dipropionate in an innovative foam vehicle","volume":"134","author":"Hollesen Basse L","year":"2014","journal-title":"J Invest Dermatol"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13859"},{"key":"e_1_2_7_12_1","first-page":"1468","article-title":"Efficacy and safety of calipotriene plus betamethasone diproprionate aerosol foam in patients with psoriasis vulgaris\u2013a randomized phase III study (PSO\u2010FAST)","volume":"14","author":"Leonardi C","year":"2015","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.3109\/09546634.2015.1083935"},{"key":"e_1_2_7_14_1","first-page":"34","article-title":"Fixed combination aerosol foam calcipotriene 0.005% (Cal) plus betamethasone dipropionate 0.064% (BD) is more efficacious than Cal or BD aerosol foam alone for psoriasis vulgaris: a randomized, double\u2010blind, multicenter, three\u2010arm, phase 2 study","volume":"9","author":"Lebwohl M","year":"2016","journal-title":"J Clin Aesthet Dermatol"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.2165\/11538370-000000000-00000"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2012.05.004"},{"key":"e_1_2_7_17_1","unstructured":"PhillippoDM AdesAE DiasSet\u00a0al.NICE DSU technical support document 18: methods for population\u2010adjusted indirect comparisons in submission to NICE. [WWW document]2016. URLhttp:\/\/www.nicedsu.org.uk(last accessed: 25 April 2018)."},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-017-0070-6"},{"issue":"10","key":"e_1_2_7_19_1","first-page":"abstract 1245","article-title":"Comparison of secukinumab vs adalimumab in a cost per responder analysis based on a matching\u2010adjusted indirect comparison of efficacy data for the treatment of psoriatic arthritis at 48\u00a0weeks from the US perspective","volume":"68","author":"Greenberg JD","year":"2016","journal-title":"Arthritis Rheumatol"},{"issue":"10","key":"e_1_2_7_20_1","first-page":"abstract 1738","article-title":"Secukinumab for the treatment of psoriatic arthritis: comparative effectiveness versus adalimumab using a matching\u2010adjusted indirect comparison","volume":"68","author":"Nash P","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.3111\/13696998.2013.768530"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.06.057"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.06.056"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2009.03.027"},{"key":"e_1_2_7_25_1","first-page":"801","article-title":"Efficacy and safety of apremilast in patients with moderate plaque psoriasis with lower BSA: week\u00a016 results from the UNVEIL study","volume":"16","author":"Strober B","year":"2017","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2016.1273469"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.12453"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2012.04596.x"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2012.06.035"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/ddg.13152"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2008.02.039"},{"key":"e_1_2_7_32_1","unstructured":"National Institute for Health and Care Excellence.Apremilast for treating moderate to severe plaque psoriasis. [WWW document] Technology appraisal guidance TA419. URLhttps:\/\/www.nice.org.uk\/guidance\/ta419(last accessed: 14 May 2018)."},{"issue":"1","key":"e_1_2_7_33_1","first-page":"AB240","article-title":"Real\u2010world efficacy and safety of calcipotriene and betamethasone dipropionate foam 0.005%\/0.064% (Cal\/BD foam) in the treatment of adult psoriasis in the United States","volume":"3","author":"Wu JJ","year":"2018","journal-title":"J Am Acad Dermatol"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjdv.15369","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.15369","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jdv.15369","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.15369","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,10]],"date-time":"2023-09-10T08:12:30Z","timestamp":1694333550000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.15369"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,19]]},"references-count":32,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["10.1111\/jdv.15369"],"URL":"https:\/\/doi.org\/10.1111\/jdv.15369","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,19]]},"assertion":[{"value":"2018-08-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-11-02","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-03-19","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}